ID

34290

Descrizione

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01831765

collegamento

https://clinicaltrials.gov/show/NCT01831765

Keywords

  1. 16/01/19 16/01/19 -
Titolare del copyright

see on clinicaltrials.gov

Caricato su

16 gennaio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Diabetes NCT01831765

Eligibility Diabetes NCT01831765

  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01831765
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 1 diabetes (diagnosed clinically) for 12 months or longer at the time of screening (visit 1)
Descrizione

ID.1

Tipo di dati

boolean

currently treated with a basal-bolus insulin regimen for at least 12 months prior to screening (visit 1)
Descrizione

ID.2

Tipo di dati

boolean

currently treated with a basal insulin analogue (any regimen of insulin detemir or insulin glargine) for at least 4 months prior to screening (visit 1)
Descrizione

ID.3

Tipo di dati

boolean

hba1c 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory
Descrizione

ID.4

Tipo di dati

boolean

body mass index (bmi) below or equal to 35.0 kg/m^2
Descrizione

ID.5

Tipo di dati

boolean

Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
use of any anti-diabetic drug other than insulin within the last 3 months prior to screening (visit 1)
Descrizione

ID.6

Tipo di dati

boolean

recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the investigator, or hospitalisation for diabetic ketoacidosis during the previous 6 months prior to screening (visit 1)
Descrizione

ID.7

Tipo di dati

boolean

cardiovascular disease, within the last 6 months prior to screening (visit 1), defined as stroke, decompensated heart failure new york heart association (nyha) class iii or iv, myocardial infarction, unstable angina pectoris, coronary arterial bypass graft or angioplasty
Descrizione

ID.8

Tipo di dati

boolean

Similar models

Eligibility Diabetes NCT01831765

  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01831765
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
type 1 diabetes (diagnosed clinically) for 12 months or longer at the time of screening (visit 1)
boolean
ID.2
Item
currently treated with a basal-bolus insulin regimen for at least 12 months prior to screening (visit 1)
boolean
ID.3
Item
currently treated with a basal insulin analogue (any regimen of insulin detemir or insulin glargine) for at least 4 months prior to screening (visit 1)
boolean
ID.4
Item
hba1c 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory
boolean
ID.5
Item
body mass index (bmi) below or equal to 35.0 kg/m^2
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
use of any anti-diabetic drug other than insulin within the last 3 months prior to screening (visit 1)
boolean
ID.7
Item
recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the investigator, or hospitalisation for diabetic ketoacidosis during the previous 6 months prior to screening (visit 1)
boolean
ID.8
Item
cardiovascular disease, within the last 6 months prior to screening (visit 1), defined as stroke, decompensated heart failure new york heart association (nyha) class iii or iv, myocardial infarction, unstable angina pectoris, coronary arterial bypass graft or angioplasty
boolean

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial